Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Almirall, S.A., Ronda General Mitre, 151, 08022 Barcelona, Spain
Solaraze 3%, gel.
| Pharmaceutical Form |
|---|
|
Gel. A clear, transparent, colourless or pale yellow gel. |
Each gram contains 30 mg diclofenac sodium (3% w/w).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Diclofenac |
Diclofenac is a non-steroidal anti-inflammatory drug. The mechanism of action of diclofenac in AK may be related to the inhibition of the cycloxygenase pathway leading to reduced prostaglandin E2 (PGE2) synthesis. In addition, immunohistochemistry (IHC) from skin biopsies ac revealed that the clinical effects of diclofenac in AK are primarily due to anti-inflammatory, anti-angiogenic and possibly anti-proliferative effects and apoptosis-inducing mechanisms. |
| List of Excipients |
|---|
|
Sodium hyaluronate |
The product is supplied in an epoxy-phenolic lined sealed aluminium tube with a white polypropylene screw on cap with a pierced tip, in 25 g, 50 g, 60 g, 90 g and 100 g sizes.
Not all pack sizes may be marketed.
Almirall, S.A., Ronda General Mitre, 151, 08022 Barcelona, Spain
PL 16973/0012
1 September 2000 / 25 July 2007
| Drug | Countries | |
|---|---|---|
| SOLARAZE | Austria, Australia, Spain, Finland, France, Ireland, Italy, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
